This Plain Language Summary of Publication article (PLSP) from Immunotherapy, highlights findings from the SHAMAL study, the first to assess the safety of reducing inhaled corticosteroid doses in people with severe eosinophilic asthma controlled with benralizumab. High-dose corticosteroids can cause side effects, and asthma guidelines suggest lowering doses for those responding well to biologics like benralizumab. However, SHAMAL aimed to provide evidence on the safety of this practice and the best approach, as none currently exists.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study’ and was published in The Lancet.

Visit Lancet using the link to read the original article.